Aviptadil: A Literature Course on a Synthetic VIP Peptide

Aviptadil appears in the published record mainly as an investigational intravenous drug for severe respiratory failure, and secondarily as a component of an intracavernosal combination product. This course organises the peer-reviewed literature into six modules, describes what each study actually measured, and closes with what the studies did not test. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no outcome described below should be read as an expected result.

Module 1: What Aviptadil Is and How It Has Been Studied

Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP), a 28-amino-acid neuropeptide that occurs naturally in humans and is found in high concentration in lung tissue. Because it reproduces an endogenous sequence rather than modifying one, it is usually classified as a peptide replacement or peptide agonist rather than an analogue. A 2022 review of the compound's anticipated pharmacological role described aviptadil as a synthetic VIP intended to act at the peptide's native receptors (PMID 34846667).

Forms and manufacturing described in the literature

Three delivery routes appear across the verified papers. Intravenous infusion dominates the critical-care literature, including a randomised placebo-controlled trial in the USA (PMID 37348524) and a 60-day randomised controlled trial in critical COVID-19 respiratory failure (PMID 36044317). Inhaled delivery was described in a published protocol for a randomised, placebo-controlled, multicentre trial in patients considered at high risk for ARDS (PMID 36127739) and in a 2025 report on inhaled aviptadil and lung damage (PMID 39870064). Intracavernosal injection, combined with phentolamine, was described in a 2025 urology report in refractory erectile dysfunction (PMID 40192471).

Two papers concern the molecule itself rather than its use. An analytical study compared sheathless capillary electrophoresis-mass spectrometry with nanoRP-HPLC-MS for characterising the therapeutic peptide aviptadil and its related impurities (PMID 24176753), and a 2023 paper described peptiligase as an enzyme enabling efficient chemo-enzymatic synthesis of aviptadil (PMID 37774815). Together these show that identity, purity and manufacturing route are active technical questions for this peptide, not settled details.

Limits of the evidence in Module 1

The human literature is concentrated in one clinical setting — hypoxaemic respiratory failure, mostly during the COVID-19 pandemic — and in a small urology application. There is no verified body of work here on healthy volunteers, long-term administration, or non-respiratory chronic disease, so descriptions of aviptadil as a general-purpose peptide are not supported by the papers listed.

Module 2: Mechanism as Described in the Literature

The mechanistic rationale in these papers rests on VIP receptor biology. The 2022 review described VIP as binding receptors expressed on alveolar type II cells, the cells responsible for surfactant production, and framed aviptadil's proposed activity in COVID-19 around protection of those cells, modulation of inflammatory cytokine activity, and the peptide's vasodilatory and bronchodilatory properties (PMID 34846667). The 60-day randomised trial was built on the same reasoning: researchers tested intravenous VIP in patients with critical COVID-19 respiratory failure on the premise that the peptide acts on alveolar type II cells (PMID 36044317).

A 2024 case report described aviptadil in terms of multiple simultaneous effects on oxygenation in acute respiratory distress syndrome rather than a single pathway (PMID 38370871). The inhaled-route protocol applied the same receptor logic to direct pulmonary delivery, reasoning that inhalation places the peptide at the alveolar surface in patients at high risk for ARDS (PMID 36127739). In the urology literature, the mechanism invoked is vascular: aviptadil was used with phentolamine, an alpha-blocker, as an intracavernosal vasoactive combination (PMID 40192471).

Limits of the evidence in Module 2

Every mechanistic statement above is a rationale described by authors, not a measured pathway in treated patients. None of the verified clinical papers demonstrated receptor occupancy, surfactant changes, or cytokine shifts as a confirmed mediator of any clinical result. A plausible mechanism does not establish a clinical effect, and the discordant trial results in Module 3 illustrate exactly that gap.

Module 3: Reported Outcomes by Study

The outcome literature is small, heterogeneous and internally inconsistent. The table summarises design and what each publication reported.

Regimens described

Both intravenous randomised trials used infusion rather than bolus dosing: aviptadil was given as escalating intravenous infusions delivered over roughly 12 hours on three successive days in the 60-day randomised controlled trial (PMID 36044317), and a comparable multi-day intravenous infusion schedule was used in the placebo-controlled TESICO trial (PMID 37348524). These were hospital, intensive-care regimens administered with continuous monitoring; no verified paper described any self-administered regimen.

Limits of the evidence in Module 3

The two randomised trials reached different conclusions, which is the central unresolved problem in this literature and the reason a 2025 editorial framed the question as promise versus mirage (PMID 41368453). Retrospective series and single-patient case reports cannot separate drug effect from illness trajectory or concurrent critical-care management. Positive descriptions in case-level reports carry the lowest evidentiary weight in the set, and a pooled analysis of heterogeneous small studies inherits the limitations of its inputs (PMID 41368449). No result described here should be treated as a promise of benefit.

Module 4: Aviptadil Side Effects: What Studies Report

Adverse events in this literature come almost entirely from hospitalised, critically ill populations receiving monitored intravenous infusions, which shapes both what was seen and how it was managed.

• Blood-pressure effects. VIP is described as a potent vasodilator, and the 2022 pharmacology review identified vasodilation as a core property of the peptide relevant to its clinical use (PMID 34846667). Consistent with that, the 60-day randomised controlled trial administered aviptadil as a slow, escalating infusion with haemodynamic monitoring, and researchers reported hypotension among the events tracked during infusion (PMID 36044317).
• Gastrointestinal effects. Diarrhoea has been among the adverse events reported during intravenous aviptadil infusion in the 60-day randomised controlled trial in critical COVID-19 respiratory failure (PMID 36044317), a finding consistent with the gastrointestinal actions attributed to vasoactive intestinal peptide in the pharmacology review (PMID 34846667).
• Serious adverse events and mortality in randomised comparison. The placebo-controlled TESICO trial collected safety and mortality data alongside its efficacy endpoints and reported that aviptadil did not improve the primary outcome relative to placebo in COVID-19-associated hypoxaemic respiratory failure (PMID 37348524). A 2025 systematic review and meta-analysis pooled safety and outcome data across aviptadil ARDS studies (PMID 41368449).
• Route-specific considerations. The published protocol for inhaled aviptadil specified safety monitoring as part of a randomised, placebo-controlled, multicentre design in patients at high risk for ARDS (PMID 36127739), and the intracavernosal literature involves a combination injection given by a clinician in a urology setting (PMID 40192471).

Limits of the evidence in Module 4

Adverse events in critically ill patients are difficult to attribute, because hypotension, diarrhoea and organ dysfunction are common features of the underlying illness and of concurrent treatments. The sample sizes are small by pharmacovigilance standards, follow-up rarely extended beyond 60 to 90 days, and no verified paper described long-term safety, repeated courses, use in healthy people, or safety outside a monitored clinical setting. The absence of a reported adverse event in this small literature is not evidence that it does not occur.

Module 5: Pharmacokinetics Where Data Exist

The verified set contains no dedicated human pharmacokinetic study of aviptadil — no published half-life, clearance, volume-of-distribution or bioavailability figures appear in these papers. What can be said is indirect and structural.

First, the dosing architecture of the clinical trials points to a short-lived molecule: the 60-day randomised controlled trial delivered aviptadil as prolonged infusions over roughly 12 hours on successive days rather than as single boluses (PMID 36044317), and the placebo-controlled TESICO trial likewise used multi-day intravenous infusion (PMID 37348524). Continuous infusion is the strategy typically adopted for peptides that are rapidly cleared.

Second, delivery route was treated as pharmacologically meaningful. The inhaled protocol was designed to place the peptide directly on the pulmonary epithelium in patients at high risk for ARDS rather than rely on systemic distribution (PMID 36127739), and the 2025 inhaled report addressed lung recovery through the same local route (PMID 39870064). In urology, intracavernosal injection places the peptide locally with a co-administered vasoactive agent (PMID 40192471).

Third, analytical and manufacturing chemistry is documented: the CE-MS versus nanoRP-HPLC-MS comparison characterised aviptadil and related impurities (PMID 24176753), and the peptiligase route addressed efficient chemo-enzymatic synthesis (PMID 37774815).

Limits of the evidence in Module 5

Inferring kinetics from a dosing schedule is not pharmacokinetics. Without measured concentration-time data in the verified literature, exposure, accumulation and dose-proportionality for aviptadil cannot be described here, and any numerical half-life claim would be unsupported by these papers.

Module 6: Regulatory Status, Stated Factually

Aviptadil's status differs sharply by country and by indication, and the following is factual description rather than legal advice.

1. Respiratory indications: investigational. In the United States, aviptadil for COVID-19-related respiratory failure was studied under clinical trial protocols, including a federally organised randomised placebo-controlled trial (PMID 37348524) and other randomised and observational studies (PMID 36044317, PMID 38510776). Investigational status means a product is authorised for study under a protocol, not marketed for general prescribing.
2. Erectile dysfunction: an approved combination in some jurisdictions. A fixed intracavernosal combination of aviptadil and phentolamine has been marketed in several countries outside the United States for erectile dysfunction, and a 2025 report described its use in refractory cases (PMID 40192471).
3. Research-use-only material. Peptide material labelled "research use only" is not manufactured, tested or released as a drug product for human administration. Identity and purity are non-trivial for this molecule, as the analytical comparison of CE-MS and nanoRP-HPLC-MS methods for aviptadil and its impurities illustrates (PMID 24176753).
4. Compounding. In the US framework, compounding by 503A pharmacies and 503B outsourcing facilities is restricted to substances that meet specific statutory criteria; a peptide's presence in clinical trials does not by itself make it eligible for compounding. Rules change, and this summary is not legal advice.

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and time-specific; approval for one route and indication says nothing about another. The published literature also lags regulatory decisions, so papers cited here describe study conduct rather than current marketing authorisation anywhere.

What the Studies Did Not Test

Across the verified literature, several questions remain untouched:

• Healthy people. No verified study administered aviptadil to healthy volunteers for wellness, recovery or performance purposes; the randomised trials enrolled patients with hypoxaemic respiratory failure (PMID 37348524, PMID 36044317).
• Non-hospital administration. All intravenous regimens described were infusions delivered in intensive-care settings with monitoring (PMID 36044317).
• Long-term exposure. Follow-up in the verified trials was measured in weeks to a few months, with 60-day outcomes reported in one randomised trial (PMID 36044317); chronic or repeated dosing was not evaluated.
• Non-viral ARDS and head-to-head comparisons. The observational work focused on viral-related severe ARDS (PMID 38510776), and the pooled 2025 review worked from a limited and heterogeneous evidence base (PMID 41368449).
• Mechanistic confirmation in patients. Receptor-level explanations remain rationale, as presented in the 2022 pharmacology review (PMID 34846667), not verified mediators of clinical outcome.

The honest summary of this course is that aviptadil is a synthetic copy of a human peptide with a coherent mechanistic story, one randomised trial reporting favourable 60-day outcomes, one larger randomised trial reporting no significant benefit on its primary endpoint, and a commentary literature openly debating which reading is correct (PMID 41368453). Readers with clinical questions should raise them with a licensed physician.

References

• Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis (Indian Journal of Critical Care Medicine, 2025)
• Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (The Lancet Respiratory Medicine, 2023)
• Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage? (Indian Journal of Critical Care Medicine, 2025)
• Anticipated pharmacological role of Aviptadil on COVID-19 (Environmental Science and Pollution Research International, 2022)
• The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial (Critical Care Medicine, 2022)
• Analytics of the therapeutic peptide aviptadil by sheathless CE-MS and comparison with nanoRP-HPLC-MS (Journal of Pharmaceutical and Biomedical Analysis, 2014)
• Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19 (Medical Principles and Practice, 2025)
• Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial (Trials, 2022)
• Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study (Indian Journal of Critical Care Medicine, 2024)
• Aviptadil: A multifaceted approach to mitigating hypoxemia in acute respiratory distress syndrome (Respiratory Medicine Case Reports, 2024)
• Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction (The Journal of Sexual Medicine, 2025)
• Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil (International Journal of Biological Macromolecules, 2023)